Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. News
  3. canada saskatchewan
  4. transient ischemic attack
Show results for
Products
Services
News
Articles
Refine by
Date

Transient Ischemic Attack Articles & Analysis

2 news found
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...

ByBayer AG

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its FXIa inhibitor, with the goal of offering a ...

ByBayer AG

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you